Medical and Pharmacy Drug Management

Latest Resource

Medical and Pharmacy Drug Management Resources

With drug spending a top concern for plan sponsors and costs rising, employers continue to explore new strategies to better manage spending. New “shared savings” vendors attempt to appeal to employers […]

With some biologic medicines topping $4 million for a single dose, specialty medicines now account for 46% of pharmaceutical spending—despite making up only 2% of prescriptions. Biosimilars, which deliver, on average, […]

Download the full Health Policy in Transit document below to learn more.

Biosimilars are the future of specialty drug therapy, costing, on average, 50% less than their biological reference products, with some exceeding 90%. While adoption has been hindered by barriers such […]

 Biosimilars are the future of specialty drug therapy, costing, on average, 50% less than their biological reference products, with some exceeding 90%. While adoption has been hindered by barriers such […]

Pulse of the Purchaser, a national survey of employers, was conducted with member coalitions from July-August 2025 with 324 responses from private and public employers and purchasers across the country. […]

Coalitions In Action

Membership in the National Alliance is a catalyst for state and regional coalitions and their employer/purchaser members to advance key initiatives. Together, they leverage their collective influence to drive health, equity and value.

Pharmacy and Medical Drugs

Defining and Driving Value

The National Alliance works with policymakers, employers/purchasers, and other stakeholders across the pharmacy and medical drug supply chain to influence competition, transparency, and value. Current issues of focus include pharmacy benefit manager (PBM) performance, contracting and formulary management, biosimilars, reducing waste, pharmacogenomics, and value-based benefit design.

The initiatives focus on practices affecting both pharmacy and medical benefits, with a strong emphasis on the rising costs of healthcare, hospital pricing, and prescription drugs. For example, the National Alliance has recently been engaging with policymakers to provide insights on the 340B program, its impact on escalating healthcare expenses for working families and employers, and potential areas for reform.

Explore these additional resources for a deeper look at the 340B program’s impact on healthcare costs and reform initiatives.

Stay current with National Alliance

Get updates on health policy, delivery and payment reform, and whole person health trends sent directly to your inbox.